ERBB2 and breast cancer: Previously untreated female patients with early HER2-positive breast cancers (n = 827) who have completed four cycles of run-in anthracycline-based chemotherapy were assigned 1:1 to receive paclitaxel plus either the biosimilar ABP 980 or the reference trastuzumab in the neoadjuvant phase.